Abnova (Taiwan) Corporation. Stock Taipei Exchange
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- TWD | - |
May. 09 | Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Abnova Corporation Announces Establishment of Risk Management Committee | CI |
Sales 2022 | 412M 12.68M | Sales 2023 | 382M 11.77M | Capitalization | 2.13B 65.48M |
---|---|---|---|---|---|
Net income 2022 | 74M 2.28M | Net income 2023 | 43M 1.32M | EV / Sales 2022 | 5.2 x |
Net cash position 2022 | 356M 10.96M | Net cash position 2023 | 415M 12.8M | EV / Sales 2023 | 4.48 x |
P/E ratio 2022 |
33.5
x | P/E ratio 2023 |
48.8
x | Employees | - |
Yield 2022 |
1.94% | Yield 2023 |
2.05% | Free-Float | 73.71% |
Managers | Title | Age | Since |
---|---|---|---|
Pei Ju Jih
CEO | Chief Executive Officer | - | 18-06-30 |
Wilber Huang
CHM | Chairman | 58 | - |
I Ling Tung
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yueh Hung Chen
BRD | Director/Board Member | 60 | 20-06-18 |
Wilber Huang
CHM | Chairman | 58 | - |
Jia Hsie Lin
BRD | Director/Board Member | 73 | 17-06-22 |
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.67% | 12.27B |